Cardinal Health announced on May 12 that it had reached a distribution agreement to sell Biosensors’ coronary stents in Europe, the Middle East, Africa, Australia and New Zealand.
Cordis, Cardinal Health’s interventional vascular business, will sell drug-eluting stents to treat patients undergoing PCIs.
It is the first time Cordis will sell drug-eluting stents since June 2011, when the company discontinued manufacturing its Cypher and Cypher Select sirolimus-eluting stents and developing its Nevo drug-eluting stents.
In October 2015, Cardinal Health completed its nearly $2 billion acquisition of Cordis, which Johnson & Johnson had owned.
During the next few months, Cordis will offer Biosensors’ coronary stents in select European countries, Australia and New Zealand. The deal includes the following stents from Biosensors: the BioFreedom polymer-free drug-coated stent, the BioMatrix NeoFlex drug-eluting stent, the BioMatrix Alpha cobalt chromium drug-eluting stent with an abluminal bio-absorbable coating and the Chroma cobalt chromium bare metal stent.
Cordis will eventually offer the stents under the Lumeno private label in additional European countries, the Middle East, Africa and other parts of the world.
Cardinal Health said it had agreed to a “long-term” partnership with Biosensors, but it did not say how long the partnership would last.